[(1R,2S,3S,4R,5S,6R,7R,8R,11R,13R,14S,17S,20S,21R)-5,7,14-trihydroxy-6,10,14,21-tetramethyl-19-oxo-18-oxapentacyclo[15.2.2.02,13.03,11.04,8]henicos-9-en-20-yl] (2S)-2-(3-acetamidopropanoylamino)-3-(3-methylimidazol-4-yl)propanoate

Term ID

CHEBI:208632

Synonyms

[(1R,2S,3S,4R,5S,6R,7R,8R,11R,13R,14S,17S,20S,21R)-5,7,14-trihydroxy-6,10,14,21-tetramethyl-19-oxo-18-oxapentacyclo[15.2.2.02,13.03,11.04,8]henicos-9-en-20-yl] (2S)-2-(3-acetamidopropanoylamino)-3-(3-methylimidazol-4-yl)propanoate

Definition

References

Chemspider:78437922

Ontology

ChEBI ( EBI )

Relationships

is a type of: peptide

peptide Show first 5 Terms

Phenotype

Phenotype resulting from [(1R,2S,3S,4R,5S,6R,7R,8R,11R,13R,14S,17S,20S,21R)-5,7,14-trihydroxy-6,10,14,21-tetramethyl-19-oxo-18-oxapentacyclo[15.2.2.02,13.03,11.04,8]henicos-9-en-20-yl] (2S)-2-(3-acetamidopropanoylamino)-3-(3-methylimidazol-4-yl)propanoate

Phenotype where environments contain [(1R,2S,3S,4R,5S,6R,7R,8R,11R,13R,14S,17S,20S,21R)-5,7,14-trihydroxy-6,10,14,21-tetramethyl-19-oxo-18-oxapentacyclo[15.2.2.02,13.03,11.04,8]henicos-9-en-20-yl] (2S)-2-(3-acetamidopropanoylamino)-3-(3-methylimidazol-4-yl)propanoate

Phenotype modified by environments containing [(1R,2S,3S,4R,5S,6R,7R,8R,11R,13R,14S,17S,20S,21R)-5,7,14-trihydroxy-6,10,14,21-tetramethyl-19-oxo-18-oxapentacyclo[15.2.2.02,13.03,11.04,8]henicos-9-en-20-yl] (2S)-2-(3-acetamidopropanoylamino)-3-(3-methylimidazol-4-yl)propanoate

Phenotype affecting [(1R,2S,3S,4R,5S,6R,7R,8R,11R,13R,14S,17S,20S,21R)-5,7,14-trihydroxy-6,10,14,21-tetramethyl-19-oxo-18-oxapentacyclo[15.2.2.02,13.03,11.04,8]henicos-9-en-20-yl] (2S)-2-(3-acetamidopropanoylamino)-3-(3-methylimidazol-4-yl)propanoate

Human Disease Model